Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 20 3868 9735
ISSN: 2155-9554
+44 20 3868 9735
Andrea Kovacikova Curkova
Dermatovenerologist, Researcher, Department of Dermatology and Venerology,
Faculty of Medicine, Bratislava, Mickiewiczova 13 Bratislava, 81369
Slovakia
Research Article
Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab
Author(s): Peter Kozub, Andrea Kovacikova Curkova, Maria Zuzulova and Maria SimaljakovaPeter Kozub, Andrea Kovacikova Curkova, Maria Zuzulova and Maria Simaljakova
Background: Infliximab is the fastest acting biological agent in psoriasis treatment due to the possibility of intravenous administration and a well-conducted induction phase of treatment (week 0, 2, and 6). Another advantage is the weight-based dosing. However, disadvantages include the risk of infusion reactions and the production of neutralizing antibodies that are responsible for the secondary loss of efficacy.
Objectives: To analyze the dynamics of infliximab levels during one maintenance interval as well as the levels of anti-infliximab antibodies in patients with psoriasis treated with infliximab for a period of at least 22 weeks.
Methods: We followed 25 patients with psoriasis treated with infliximab for a period of at least 22 weeks at a dose of 5 mg/kg. Based on the clinical picture at the time of blood s.. Read More»
DOI:
10.4172/2155-9554.1000214
